UNITED STATES
                SECURITIES AND EXCHANGE COMMISSION
                     Washington, D. C. 20549

                           Form 10-QSB


[X]     Quarterly Report Under Section 13 or 15(d) of the Securities Exchange
        Act of 1934

              For Quarter Ended: September 30, 2001

                                OR

[ ]     Transition Report Pursuant to Section 13 or 15(d) of the Securities
        Exchange Act of 1934



                  Commission File No.  000-30991

             SKINOVATION PHARMACEUTICAL INCORPORATED
               (Name of registrant in its charter)


        NEVADA                                          87-0458170
(State of incorporation)             (I. R. S. Employer Identification No.)

                        525 SOUTH 300 EAST
                    SALT LAKE CITY, UTAH 84111
                          (801) 323-2395
  (Address and telephone number of principal executive offices
                 and principal place of business)


     Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.  Yes [X]   No [   ]

     As of November 5, 2001, the Registrant had a total of 708,000 shares of
common stock issued and outstanding.

<PAGE>

                 PART I:   FINANCIAL INFORMATION


ITEM 1: FINANCIAL STATEMENTS

      The financial information set forth below with respect to our statements
of operations for the three and nine month periods ended September 30, 2001
and 2000 are unaudited.  This financial information, in the opinion of
management, includes all adjustments consisting of normal recurring entries
necessary for the fair presentation of such data.  The results of operations
for the nine months ended September 30, 2001, are not necessarily indicative
of results to be expected for any subsequent period.











                                2
<PAGE>











                 Skinovation Pharmaceutical, Inc.
                  (A Development Stage Company)
                       Financial Statements
                        September 30, 2001


<PAGE> 3


                 Skinovation Pharmaceutical, Inc.
                  (A Development Stage Company)
                          Balance Sheets



                              ASSETS

                                                  September 30,  December 31,
                                                      2001           2000
                                                  ------------- -------------
                                                   (Unaudited)

CURRENT ASSETS                                    $          -  $          -
                                                  ------------- -------------

  TOTAL ASSETS                                    $          -  $          -
                                                  ============= =============


               LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES

Accounts Payable - Related Party                        28,776        28,776
                                                  ------------- -------------

  Total Liabilities                                     28,776        28,776
                                                  ------------- -------------

STOCKHOLDERS' EQUITY

Common Stock, $.001 par value; 50,000,000
  shares authorized; 708,000 shares issued
  and outstanding, respectively                            708           708

Additional Paid in Capital                              25,148        25,148

Deficit Accumulated During the Development Stage       (54,632)      (54,632)
                                                  ------------- -------------

  Total Stockholders' Equity                           (28,776)      (28,776)
                                                  ------------- -------------

  TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY      $          -  $          -
                                                  ============= =============




<PAGE> 4






                 Skinovation Pharmaceutical, Inc.
                  (A Development Stage Company)
                     Statement of Operations
                           (Unaudited)

<TABLE>
<CAPTION>


                                                                                    From
                           For the        For the       For the       For the       Inception on
                           three months   three months  nine months   nine months   January 15,
                           ended          ended         ended         ended         1988 through
                           September 30,  September 30, September 30, September 30, September 30,
                           2001           2000          2001          2000          2001
                           -------------- ------------- ------------- ------------- -------------
<S>                        <C>            <C>           <C>           <C>           <C>
REVENUES                   $           -  $          -  $          -  $          -  $     27,937
                           -------------- ------------- ------------- ------------- -------------
EXPENSES
  General & Administrative             -         5,500             -         5,500       119,644
                           -------------- ------------- ------------- ------------- -------------

    TOTAL EXPENSES                     -         5,500             -         5,500       119,644
                           -------------- ------------- ------------- ------------- -------------

NET LOSS BEFORE
 DISCONTINUED OPERATIONS               -        (5,500)            -        (5,500)      (91,707)
                           -------------- ------------- ------------- ------------- -------------
GAIN ON DISPOSAL OF
 OPERATIONS                            -             -             -             -        37,075
                           -------------- ------------- ------------- ------------- -------------

NET INCOME(LOSS)           $           -  $     (5,500) $          -  $     (5,500) $    (54,632)
                           ============== ============= ============= ============= =============

NET LOSS PER SHARE         $           -  $         (0) $          -  $         (0) $      (0.11)
                           ============== ============= ============= ============= =============

WEIGHTED AVERAGE SHARES
  OUTSTANDING                    708,000       699,667       708,000       668,556       492,982
                           ============== ============= ============= ============= =============



</TABLE>
<PAGE> 5
<TABLE>
<CAPTION>

                     Skinovation Pharmaceutical, Inc.
                      (A Development Stage Company)
                         Statement of Cash Flows
                               (Unaudited)


                                                                                From
                                                   For the nine months ended    Inception on
                                                          September 30,         January 15, 1988
                                                   ---------------------------  to September 30,
                                                      2001           2000       2001
                                                   ------------- -------------  ---------------
<S>                                                <C>           <C>            <C>
Cash Flows from Operating Activities

  Net Loss                                         $          -  $     (5,500)  $      (54,632)
  Less Non-Cash Items:
  Shares issued for services                                  -         5,500           10,433
  Shares issued for debt payment                              -             -            1,424
  Increase(Decrease) in accounts payable                      -             -           28,776
  Loss on disposal of PP&E                                    -             -            5,263
                                                   ------------- -------------  ---------------

  Net Cash Provided(Used) by Operating Activities             -             -           (8,736)
                                                   ------------- -------------  ---------------
Cash Flows from Investing Activities
  Cash paid for PP&E                                          -             -           (5,264)
                                                   ------------- -------------  ---------------

  Net Cash Provided(Used) by Investing Activities             -             -           (5,264)
                                                   ------------- -------------  ---------------
Cash Flows from Financing Activities
  Cash paid for offering costs                                -             -           (7,000)
  Shares issued for cash                                      -             -           21,000
                                                   ------------- -------------  ---------------

  Net Cash Provided(Used) by Financing Activities             -             -           14,000
                                                   ------------- -------------  ---------------

Increase in Cash                                              -             -                -

Cash and Cash Equivalents at Beginning of Period              -             -                -
                                                   ------------- -------------  ---------------

Cash and Cash Equivalents at End of Period         $          -  $          -   $            -
                                                   ============= =============  ===============

Supplemental Non-Cash Financing Transactions:

  Stock issued for debt payment                               -             -            1,424
  Stock issued for services                                   -         5,500           10,433

Cash Paid For:
  Interest                                         $          -  $          -   $            -
  Income Taxes                                     $          -  $          -   $            -


</TABLE>
<PAGE> 6

                 Skinovation Pharmaceutical, Inc.
                  (A Development Stage Company)
                Notes to the Financial Statements
                        September 30, 2001



GENERAL

Skinovation Pharmaceutical, Inc.(the Company) has elected to omit
substantially all footnotes to the financial statements for the nine months
ended September 30, 2001 since there have been no material changes (other than
indicated in other footnotes) to the information previously reported by the
Company in their Annual Report  filed on Form 10-KSB for the year ended
December 31, 2000.

UNAUDITED INFORMATION

The information furnished herein was taken from the books and records of the
Company without audit.  However, such information reflects all adjustments
which are of a normal recurring nature and are, in the opinion of management,
necessary to properly reflect the results of the interim period presented.
The information presented is not necessarily indicative of the results from
operations expected for the full fiscal year.




<PAGE> 7

      In this report references to "Skinovation," "we," "us," and "our" refer
to Skinovation Pharmaceutical Incorporated.

                    Forward Looking Statements

      This Form 10-QSB contains certain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.  For this
purpose any statements contained in this Form 10-QSB that are not statements
of historical fact may be deemed to be forward-looking statements.  Without
limiting the foregoing, words such as "may," "will," "expect," "believe,"
"anticipate," "estimate" or "continue" or comparable terminology are intended
to identify forward-looking statements.  These statements by their nature
involve substantial risks and uncertainties, and actual results may differ
materially depending on a variety of factors, many of which are not within
Skinovation's control.  These factors include but are not limited to economic
conditions generally and in the market which Skinovation may participate;
competition within Skinovation's chosen market and failure by Skinovation to
successfully develop business relationships.


ITEM 2:  PLAN OF OPERATIONS

      We are a development stage company with no assets, we have experienced
losses since our inception and we are dependent on financing to continue our
operations.  For the fiscal year ended December 31, 2000, and the nine and
three month periods ended September 30, 2001, we had no cash on hand and total
current liabilities of $28,776.  The $28,766 account payable is related to
accounting and legal fees paid on our behalf by a related party in fiscal year
1999.

      We have no commitments for capital expenditures for the next twelve
months.  During the next twelve months we believe that our current cash needs
may be met by loans from our directors, officers and stockholders.  We may
repay these loans, costs of services  and advancements with cash, if
available, or we may convert them into common stock.

      Our management intends to actively pursue business opportunities during
the next twelve months.  All risks inherent in new and inexperienced
enterprises are inherent in our business.  We have not made a formal study of
the economic potential of any business.  At the present, we have not
identified any assets or business opportunities for acquisition.

      Based on current economic and regulatory conditions, management believes
that it is possible, if not probable, for a company like ours, without many
assets or liabilities, to negotiate a merger or acquisition with a viable
private company.  The opportunity arises principally because of the high legal
and accounting fees and the length of time associated with the registration
process of "going public".  However, should any of these conditions change, it
is very possible that there would be little or no economic value for anyone
taking over control of Skinovation.

      Potential investors must recognize that because of our limited capital
available for investigation and management's limited experience in business
analysis we may not discover or adequately evaluate adverse facts about the
business opportunity to be acquired.  Also, we intend to concentrate our
acquisition efforts on properties or businesses that we believe to be
undervalued or that we believe may realize a substantial benefit from being
publicly owned.  Investors should expect that any acquisition candidate may
have little or no operating history, or a history of losses or low
profitability.


                                8
<PAGE>

      It is emphasized that our management may effect transactions having a
potentially adverse impact upon our shareholders pursuant to the authority and
discretion of our management to complete acquisitions without submitting any
proposal to the stockholders for their consideration.

      Should a merger or acquisition prove unsuccessful, it is possible that
we may decide not to pursue further acquisition activities and management may
abandon its activities and our shares would become worthless.


                             PART II
                        OTHER INFORMATION

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

(a)   Exhibits

Exhibit Number     Description
    3.1            Articles of Incorporation, dated January 15, 1988
                   (Incorporated by reference to exhibit 3.1 of the Form-SB,
                   filed July 11, 2000)

    3.2            Certificate of Amendment, dated August 5, 1992
                   (Incorporated by reference to exhibit 3.2 of the Form-SB,
                   filed July 11, 2000)

    3.3            Bylaws of Skinovation Pharmaceutical Incorporated
                   (Incorporated by reference to exhibit 3.3 of the Form-SB,
                   filed July 11, 2000)

(b)    Reports on Form 8-K

       None.



                            SIGNATURES

      In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.


                                    Skinovation Pharmaceutical Incorporated


         11/07/01                      /s/ John W. Peters
Date_________________________    By: ______________________________________
                                     John W. Peters, President and Director






                                9